Executive Summary
This batch adds $3.3B in federal contract obligations, predominantly bullish (9/12), bolstering backlogs in defense shipbuilding, space, healthcare services, and construction with long-term visibility to 2033. Key upside from unexercised options exceeding $4B potential across top awards (e.g., Austal $3.3B ceiling, Booz Allen $531M).
Low average outlays (~10-20% of obligations) signal early-stage execution risks but stable revenue ramps for primes like Austal, Lockheed, and Noridian.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from February 27, 2026.
Investment Signals (5)
- Shipbuilding backlog surge (HIGH)▲
Austal USA's $1.2B OPC contract (up to $3.3B options) and DDL Omni's $72M Coast Guard support highlight DHS commitment to vessel production/sustainment.
- Space mission revenue visibility (HIGH)▲
Lockheed's $348M Lucy mission (to 2033) and Booz Allen's $177M Space Systems support (up to $531M) provide multi-year NASA/USSF funding stability.
- Healthcare services tailwinds (MEDIUM)▲
Noridian ($407M CMS improper payments to 2027), Veterans Evaluation ($166M VA exams, 98% outlayed), and Planned Systems ($162M VA IT) affirm demand for medical/IT evaluation.
- Border/construction commitments (HIGH)▲
Granite Construction's $169M CBP barrier (to 2028) and Whiting-Turner's $198M GSA facility reimagining signal infrastructure spending.
- Student loan servicing ramp (MEDIUM)▲
Nelnet's $79M Ed Dept order shows outlays exceeding obligation ($158M), indicating accelerated federal student aid disbursements.
Risk Flags (3)
- Execution [HIGH RISK]▼
Low outlays (avg ~15% of obligations, e.g., Austal $61M/$1.2B, Family Health $3M/$233M) signal potential delays in 8/12 contracts.
- Execution [HIGH RISK]▼
Fixed-price structures in shipbuilding/construction (Austal, Granite, Whiting-Turner) expose to cost overruns amid inflation/labor shortages over 3-8 years.
- Execution [MEDIUM RISK]▼
Long durations to 2033 (Lockheed) or 2030 (Austal) with subawards >$500M total heighten funding continuity and subcontractor risks.
Opportunities (3)
- ◆
$4B+ in unexercised options (e.g., Austal $2.1B addl, Booz Allen $355M, Family Health $500M) for scaling revenue.
- ◆
Follow-ons in border security (Granite CBP), improper payments (Noridian CMS), and VA services amid rising demand.
- ◆
Near-complete outlays (e.g., Veterans Eval 98%, Nelnet excess) enable immediate cash conversion.
Sector Themes (3)
- ◆
DHS Coast Guard/CBP awards total $1.5B (Austal, Granite, DDL) emphasize OPC production and border infrastructure.
- ◆
$1B+ across CMS/VA/CDC (Noridian, Veterans Eval, Planned, NYC Health) targets improper payments, exams, IT support.
- ◆
NASA/USSF commitments (Lockheed Lucy $348M to 2033, Booz $177M GSIS) with $1B subawards signal ecosystem growth.
Watch List (3)
- 👁
{"entity"=>"Austal USA / Austal Limited", "reason"=>"Largest award $1.2B (up to $3.3B) with only 5% outlayed; shipbuilding execution critical.", "trigger"=>"Option exercises or outlay >20% of obligation"}
- 👁
{"entity"=>"Booz Allen Hamilton", "reason"=>"$177M Space Systems (up to $531M ceiling) at early stage with $62M subawards.", "trigger"=>"Performance period extension to 2028"}
- 👁
{"entity"=>"Lockheed Martin", "reason"=>"Lucy mission to 2033 provides decade-long NASA revenue amid subaward dependencies.", "trigger"=>"Subsequent NASA astrophysics awards"}
Get daily alerts with 5 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 12 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals